Moxifloxacin 1a Pharma

Moxifloxacin, the active ingredient in Moxifloxacin 1a Pharma, is a fluoroquinolone antibiotic presented as an oral tablet for systemic use. It treats a range of bacterial infections, including community‑acquired pneumonia, acute bacterial sinusitis, exacerbations of chronic bronchitis, and skin and skin‑structure infections in adult patients.

GNH USA supplies Moxifloxacin 1a Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to EU and other markets.

Moxifloxacin is a fluoroquinolone antibiotic used to treat bacterial infections of the respiratory and skin systems. - Community‑acquired bacterial pneumonia: Improves clinical cure rates and reduces bacterial load in adult patients. - Acute bacterial sinusitis: Relieves sinus inflammation by eradicating the causative pathogens. - Acute bacterial exacerbation of chronic bronchitis: Shortens duration of symptoms and prevents progression. - Skin and skin structure infections: Achieves bacterial clearance in cellulitis, abscesses and wound infections.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Nausea - Diarrhea - Headache - Dizziness - Abdominal pain - Rash Serious or Rare Side Effects: - Tendon rupture or tendonitis - QT interval prolongation leading to arrhythmia - Severe allergic reactions such as anaphylaxis - Clostridioides difficile‑associated diarrhea - Hepatic dysfunction - Peripheral neuropathy

When prescribing Moxifloxacin, clinicians should consider several safety factors. - Renal impairment: Adjust therapy based on renal function and monitor creatinine. - History of tendon disorders: Avoid use in patients with prior tendon inflammation or recent fluoroquinolone exposure. - Cardiac risk: Use cautiously in patients with known QT prolongation or electrolyte abnormalities. - Concomitant CYP450 inhibitors: Review potential for increased plasma levels. - Pregnancy and lactation: Use only if benefits outweigh risks; data are limited. - Store at ambient temperature: Keep below 25 °C, in original packaging, protected from moisture and light.

Moxifloxacin can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity. Major Interactions (Avoid): - Antacids containing aluminum or magnesium: Reduce absorption of moxifloxacin. - Corticosteroids: Increased risk of tendon rupture. - Warfarin: May potentiate anticoagulant effect, monitor INR. Moderate Interactions (Monitor Closely): - Non‑cardiac QT‑prolonging drugs: May have additive effect on QT interval. - Theophylline: May increase plasma concentrations of theophylline. - Cytochrome P450 inducers (e.g., rifampin): May lower moxifloxacin levels.